Heparin Therapeutics in Sepsis Management

Sepsis arises from a dysregulated host response to infection, leading to simultaneous activation of inflammatory, immune and coagulation pathways. Heparin, a sulphated glycosaminoglycan commonly used as an anticoagulant, has emerged as a multifaceted agent in sepsis management. Beyond its capacity to inhibit thrombin and factor Xa via antithrombin, heparin interferes with key inflammatory mediators such as histones, high-mobility group box 1 and heparin-binding protein, modulates endothelial barrier function and attenuates vascular permeability. Clinical investigations have explored unfractionated and low-molecular-weight formulations, as well as heparin derivatives with reduced anticoagulant potency, to balance antithrombotic benefits against bleeding risk. Recent advances focus on identifying biomarkers of coagulation activation to stratify patients most likely to benefit, optimising dose and timing of administration, and elucidating molecular mechanisms underpinning heparin’s pleiotropic actions. The global burden of sepsis, coupled with the accessibility of heparin formulations, underscores the importance of refining this therapeutic approach through rigorous trials and translational research.

Research from Nature Portfolio

A comprehensive meta-analysis of randomised controlled trials evaluated low-molecular-weight heparin in septic patients and found a significant reduction in 28-day mortality and disease severity scores, albeit with an increase in bleeding events. Pooled data demonstrated improved coagulation profiles, shorter prothrombin times and enhanced platelet recovery. Subgroup analyses highlighted variation in benefit according to baseline severity and dosing regimens, underscoring the necessity for vigilant bleeding surveillance and personalised anticoagulant strategies. This foundational synthesis has informed current trial designs aimed at delineating optimal therapeutic windows and patient phenotypes for heparin intervention.

Heparin Therapeutics in Sepsis Management publication trend

The graph below shows the total number of articles in heparin therapeutics in sepsis management across all publications each year (not limited to Nature Index journals).

Technical terms

Sepsis: A life-threatening organ dysfunction caused by a dysregulated host response to infection.

Unfractionated heparin (UFH): A heterogeneous mixture of glycosaminoglycan chains that enhances antithrombin activity to inhibit thrombin and factor Xa.

Low-molecular-weight heparin (LMWH): Partially depolymerised heparin fragments with more predictable pharmacokinetics and reduced monitoring requirements.

Sepsis-induced coagulopathy (SIC): A coagulation disorder in sepsis characterised by prolonged clotting times, low platelets and heightened risk of organ dysfunction.

Meta-analysis: A statistical approach that aggregates data from multiple independent studies to derive overall effect estimates.

Heparan sulphate: A ubiquitous cell-surface glycosaminoglycan involved in inflammation, endothelial function and host–pathogen interactions.

References

1. Heparin in sepsis: current clinical findings and possible mechanisms. Frontiers in Immunology (2024).
2. Effectiveness of early heparin therapy on outcomes in critically ill patients with sepsis-induced coagulopathy. Frontiers in Pharmacology (2023).
3. Heparin, Heparan Sulphate and Sepsis: Potential New Options for Treatment. Pharmaceuticals (2023).
4. Efficacy and safety of low-molecular-weight heparin in patients with sepsis: a meta-analysis of randomized controlled trials. Scientific Reports (2016).
5. Unfractionated heparin ameliorates pulmonary microvascular endothelial barrier dysfunction via microtubule stabilization in acute lung injury. Respiratory Research (2018).